Optimizing outcomes of ACL surgery—Is autograft reconstruction the only reasonable option?

Martha M. Murray
DOI: https://doi.org/10.1002/jor.25128
2021-07-16
Journal of Orthopaedic Research
Abstract:<p>ACL injuries occur at a high frequency in the US with approximately 400,000 ACL reconstructions being performed each year<sup>1</sup>. While ACL reconstruction is our current gold standard of treatment, it does not restore joint motion<sup>2-4</sup>, or prevent the premature development of post-traumatic osteoarthritis (PTOA) in many patients<sup>5-9</sup>. Thus, new treatments for an ACL injury, which are less invasive and minimize patient morbidity, including cartilage damage, are highly desirable<sup>10,11</sup>. We have used a tissue engineered approach to stimulate ligament healing, to improve upon current treatment options<sup>12</sup>. In this review, we describe and discuss our work moving a tissue engineering strategy from the concept to bench, preclinical, clinical trials and ultimately FDA 510(k) de Novo approval, providing clinicians and patients with a viable alternative to ACL reconstruction.</p><p>This article is protected by copyright. All rights reserved.</p>
orthopedics
What problem does this paper attempt to address?